TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, ther...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Blood Adv
المؤلفون الرئيسيون: Tenshin, Hirofumi, Teramachi, Jumpei, Oda, Asuka, Amachi, Ryota, Hiasa, Masahiro, Bat-Erdene, Ariunzaya, Watanabe, Keiichiro, Iwasa, Masami, Harada, Takeshi, Fujii, Shiro, Kagawa, Kumiko, Sogabe, Kimiko, Nakamura, Shingen, Miki, Hirokazu, Kurahashi, Kiyoe, Yoshida, Sumiko, Aihara, Kenichi, Endo, Itsuro, Tanaka, Eiji, Matsumoto, Toshio, Abe, Masahiro
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2017
الموضوعات:
Immunobiology and Immunotherapy
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737122/
https://ncbi.nlm.nih.gov/pubmed/29296860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008813
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة